ArticleGene therapy2005
Angiogenesis is confined to the transient period of VEGF expression that follows adenoviral gene delivery to ischemic muscle.
Article in Gene therapy, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 71 citations in OpenAlex.
- Effect of Intramyocardial Administration of Baculovirus Encoding the Transcription Factor Tbx20 in Sheep With Experimental Acute Myocardial Infarction.Journal of the American Heart Association · 2024Article
- N-acetylcysteine differentially regulates the populations of bone marrow and circulating endothelial progenitor cells in mice with limb ischemia.European journal of pharmacology · 2020Article
- Fibroblast Growth Factor 2-A Review of Stabilisation Approaches for Clinical Applications.Pharmaceutics · 2020Review
- High-dose intramyocardial HMGB1 induces long-term cardioprotection in sheep with myocardial infarction.Drug delivery and translational research · 2019Article
- Enhanced notch signaling modulates unproductive revascularization in response to nitric oxide-angiopoietin signaling in a mouse model of peripheral ischemia.Microcirculation (New York, N.Y. : 1994) · 2019Article
- Gene-Therapeutic Strategies Targeting Angiogenesis in Peripheral Artery Disease.Medicines (Basel, Switzerland) · 2018Review
- Method for Dual Viral Vector Mediated CRISPR-Cas9 Gene Disruption in Primary Human Endothelial Cells.Scientific reports · 2017Article
- Vascular Regeneration in Ischemic Hindlimb by Adeno-Associated Virus Expressing Conditionally Silenced Vascular Endothelial Growth Factor.Journal of the American Heart Association · 2016Article
- Near-infrared II fluorescence for imaging hindlimb vessel regeneration with dynamic tissue perfusion measurement.Circulation. Cardiovascular imaging · 2014Article
- Therapeutic Angiogenesis by Gene Therapy for Critical Limb Ischemia: Choice of Biological Agent.Immunology, endocrine & metabolic agents in medicinal chemistry · 2014Article
- Short hairpin RNA gene silencing of prolyl hydroxylase-2 with a minicircle vector improves neovascularization of hindlimb ischemia.Human gene therapy · 2014Article
- Quantitative optical imaging of vascular response in vivo in a model of peripheral arterial disease.American journal of physiology. Heart and circulatory physiology · 2013Article
- Transplantation of modified human adipose derived stromal cells expressing VEGF165 results in more efficient angiogenic response in ischemic skeletal muscle.Journal of translational medicine · 2013Article
- Cell therapy of peripheral arterial disease: from experimental findings to clinical trials.Circulation research · 2013Review
- Long-term effects of hepatocyte growth factor gene therapy in rat myocardial infarct model.Gene therapy · 2012Article
- Whole-mount imaging of the mouse hindlimb vasculature using the lipophilic carbocyanine dye DiI.BioTechniques · 2012Article
- Stromal-Cell-Derived Factor-1 (SDF-1)/CXCL12 as Potential Target of Therapeutic Angiogenesis in Critical Leg Ischaemia.Cardiology research and practice · 2012Article
- Gene therapy from the perspective of systems biology.Current opinion in molecular therapeutics · 2010Review
- Human studies of angiogenic gene therapy.Circulation research · 2009Review
- Vascular regeneration by local growth factor release is self-limited by microvascular clearance.Circulation · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Therapeutic angiogenesis involves the introduction of exogenous growth factor proteins and genes into ischemic tissues to augment endogenous factors and promote new vessel growth. Positive results from studies in animal models of peripheral arterial disease (PAD) and coronary artery disease over the past decade have supported the implementation of clinical trials testing vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) proteins and genes. Although several clinical trials reported positive results, others have been disappointing and results of a recent Phase II trial of VEGF delivered by adenovirus (the RAVE trial) were negative. It has been suggested that the duration of gene expression following delivery by adenovirus may be insufficient to produce stable vessels. Here we present direct evidence in support of this using the rabbit ischemic hindlimb model injected with adenovirus encoding VEGF165. Immunohistology indicated an activation of endothelial cell cycling and proliferation 2-3 days after VEGF delivery that coincided closely with transient VEGF expression. Ki-67-positive endothelial nuclei were evident at high levels in capillaries and large vessels in muscles from treated animals. Angiography indicated increased density of both large and small vessels in Ad-VEGF-treated muscle at 1 week, but no significant differences thereafter. The early burst of endothelial proliferation was accompanied by increased nuclear fragmentation and condensation in VEGF-treated muscles, suggesting coincident apoptosis. No further endothelial cell proliferation took place after 1 week although there was still evidence of apoptosis. The results suggest that angiogenesis is confined to the short period of VEGF expression produced by adenovirus and early gains in collateralization rapidly regress to control levels when VEGF production ceases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.